AG Schittenhelm

 

Institute of Brain Research, Department of Pathology and Neuropathology, University of Tübingen, Calwer Str.3, 72074 Tübingen, Germany

 

Research interests:

Analysis of Proteins serving as a regulator of cell-matrix interaction and might be associated with tumour stage and patient survival in various malignancies. Expression analysis of factors influencing differentiation, invasion, migration and tumor progression of astrocytic neoplasias using high troughput tissue microarrays. Improving neuropathological diagnostic by screening for new tumor biomarkers which are capable to discriminate between normal and reactive tissue (mutation specific antibodies).

 

Selected Publications

 

1

Schittenhelm J, Mittelbronn M, Meyermann R, Melms A, Tatagiba M, Capper D.
Confirmation of R132H mutation of isocitrate dehydrogenase 1 as an independent prognostic factor in anaplastic astrocytoma.
Acta Neuropathol. 2011 Nov;122(5):651-2.

2

Capper D, Sahm F, Hartmann C, Meyermann R, von Deimling A, Schittenhelm J.
Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes.
Am J Surg Pathol. 2010 Aug;34(8):1199-204.

3

Capper D, Mittelbronn M, Goeppert B, Meyermann R, Schittenhelm J.
Secreted protein, acidic and rich in cysteine (SPARC) expression in astrocytic tumour cells negatively correlates with proliferation, while vascular SPARC expression is associated with patient survival.
Neuropathol Appl Neurobiol. 2010 Apr;36(3):183-97

4

Schittenhelm J, Trautmann K, Tabatabai G, Hermann C, Meyermann R, Beschorner R.
Comparative analysis of annexin-1 in neuroepithelial tumors shows altered expression with the grade of malignancy but is not associated with survival.
Mod Pathol. 2009 Dec;22(12):1600-11.

5

Gramatzki D, Pantazis G, Schittenhelm J, Tabatabai G, Köhle C, Wick W, Schwarz M, Weller M, Tritschler I.
Aryl hydrocarbon receptor inhibition downregulates the TGF-beta/Smad pathway in human glioblastoma cells.
Oncogene. 2009 Jul 16;28(28):2593-605.

6

Beschorner R, Pantazis G, Jeibmann A, Boy J, Meyermann R, Mittelbronn M, Schittenhelm J.
Expression of EAAT-1 distinguishes choroid plexus tumors from normal and reactive choroid plexus epithelium.
Acta Neuropathol. 2009 Jun;117(6):667-75.

7

Schittenhelm J, Beschorner R, Simon P, Tabatabai G, Herrmann C, Schlaszus H, Capper D, Weller M, Meyermann R, Mittelbronn M.
Diagnostic value of WT1 in neuroepithelial tumours.
Neuropathol Appl Neurobiol. 2009 Feb;35(1):69-81

8

Capper D, Mittelbronn M, Meyermann R, Schittenhelm J.
Pitfalls in the assessment of MGMT expression and in its correlation with survival in diffuse astrocytomas: proposal of a feasible immunohistochemical approach.
Acta Neuropathol. 2008 Feb;115(2):249-59.

9

Beschorner R, Schittenhelm J, Schimmel H, Iglesias-Rozas JR, Herberts T, Schlaszus H, Meyermann R, Wehrmann M.
Choroid plexus tumors differ from metastatic carcinomas by expression of the excitatory amino acid transporter-1.
Hum Pathol. 2006 Jul;37(7):854-60.

10

Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A.
Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
Acta Neuropathol. 2011 Feb;121(2):241-52.